NCT00045006View on ClinicalTrials.gov

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 2001

Primary Completion Date

December 31, 2005

Study Completion Date

July 31, 2008

Conditions
Cancer
Interventions
DRUG

vorinostat

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00045006 - Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter